BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

New data suggests researchers may have found one of their most promising candidates yet for the next generation in ...

San Antonio Breast Cancer Conference featured updates on VEGF bispecifics, oral protein degraders, and data from BeiGene, ...

Merck (NYSE: MRK) shares decreased in price Friday, on word the European Medicines Agency's Committee for Medicinal Products ...

However, these options are not curative, new tumors continue to occur, and there have been no approved systemic therapeutic .

产品活性： Bevacizumab 是一种人源化的 IgG1 单克隆抗体，高亲和力且特异性地与所有 VEGF-A 结合。 体外： ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

BioNTech shared survival data from a Phase 1b/2 trial testing BNT327 (PD-L1xVEGF bispecific) plus nab-paclitaxel in ...

Whilst a persistent cough and coughing up blood is a sign something is wrong, another symptom that's often forgotten about is ...

AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...

Mohit Bansal, an analyst from Wells Fargo, has initiated a new Buy rating on Summit Therapeutics (SMMT).Pick the best stocks and maximize your ...